Sensus Healthcare to Showcase Products at AAD Annual Meeting
Sensus Healthcare, Inc. (Nasdaq: SRTS), a leader in non-invasive and cost-effective treatments for skin conditions, will showcase its complete line of Superficial Radiotherapy (SRT) products—including the SRT-100®, SRT-100+, and SRT-100 Vision™ systems—along with innovative pre-commercial products at the 2025 American Academy of Dermatology (AAD) Annual Meeting. The event will be held March 7-11, 2025, at the Orange County Convention Center in Orlando, Florida.
At Booth #2451, Sensus invites attendees to experience “The A.I. Experience,” a futuristic, technology-focused environment that highlights the company’s latest advancements. Among the key products on display will be the SRT-100 Vision, the only FDA-cleared Image-Guided Superficial Radiotherapy (IG-SRT) system. This system is gaining recognition among dermatologists as the non-surgical solution of choice for treating non-melanoma skin cancer and keloids. With its ability to target cancerous tissue with precision, the SRT-100 Vision offers a safe, effective, and minimally invasive alternative to traditional surgical methods.
In addition to the SRT-100 Vision, Sensus will also unveil several other groundbreaking technologies at the booth. One of the most exciting new devices is a prototype handheld ultrasound system designed to help clinicians identify skin lesions. This portable ultrasound device enhances practice efficiency by providing an easy-to-use solution for detecting skin abnormalities, particularly in remote or off-site settings where access to specialized equipment may be limited. This new tool is expected to improve early detection rates and broaden the availability of diagnostic services.
Sensus will also present its work-in-progress TransDermal Infusion (TDI) product, which incorporates Sentinel™ IT Solutions capabilities. Once regulatory approval is obtained, the TDI system is set to revolutionize treatments like platelet-rich plasma (PRP) therapy for hair restoration. The TDI technology is designed to allow PRP to be painlessly applied to the scalp, providing a non-invasive, highly effective solution for individuals seeking hair restoration without the discomfort of traditional methods. Additionally, posters will be presented highlighting the potential applications of TDI for treating hyperhidrosis (excessive sweating). The system’s ability to deliver targeted treatments with minimal discomfort sets it apart from existing therapies.
“Our team is thrilled to return to the AAD Annual Meeting and share these groundbreaking technologies with the dermatology community,” said Joe Sardano, Chairman and CEO of Sensus Healthcare. “This year, we are particularly excited to showcase our new handheld ultrasound device, which expands access to skin lesion detection, even in remote areas. We invite all attendees to explore our suite of technologies at the booth and see how we are advancing the standard of care in dermatology.”
Sensus Healthcare’s commitment to innovation extends beyond product development. In recognition of the importance of ongoing education and collaboration, the company will host an exclusive dinner event on March 7, 2025. This invitation-only gathering will provide a unique opportunity for guests to engage with Sensus management and learn more about the company’s approach to skin cancer treatment. A guest speaker will also discuss the importance of skin cancer prevention and patient education, which aligns with Sensus’s mission to reduce the global impact of skin cancer.
The AAD Annual Meeting is one of the most significant events in the dermatology field, bringing together thousands of professionals for a comprehensive educational experience. With over 350 exhibitors, more than 300 educational sessions, and nearly 20,000 attendees, the event provides a platform for networking and learning about the latest advancements in dermatology. As a leading provider of non-invasive treatments for skin conditions, Sensus Healthcare is proud to contribute to this dynamic exchange of knowledge and innovation.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global leader in the development of non-invasive treatments for skin cancer, keloids, and other dermatological conditions. Utilizing its state-of-the-art superficial radiotherapy (SRT and IG-SRT) technology, Sensus offers highly effective, patient-centered treatment options that are safe, precise, and adaptable to various clinical settings. With a focus on advancing radiation oncology, the company is committed to providing healthcare providers with the tools they need to deliver superior care to their patients. Sensus’s innovations in non-invasive skin cancer treatments have helped to redefine the standard of care in dermatology, offering patients and providers a better alternative to traditional surgical methods.
With a growing portfolio of cutting-edge products and a dedication to improving patient outcomes, Sensus Healthcare continues to lead the way in advancing skin health through technology-driven solutions.
